ASML's Premium Valuation Confronts AI Growth and Geopolitical Perils

What happened

ASML's stock price has surged to $1,423.54, trading at 46.8x P/E, as investors bank on AI-driven semiconductor capex fueling demand for its EUV lithography systems. A recent article highlights that revenue growth and margins are rising due to EUV systems making up a larger share of sales, painting a bullish picture. However, DeepValue analysis reveals concrete risks: export controls and supply chain dependencies, like the sole-source optics from Carl Zeiss SMT, threaten shipment cadence and service monetization. Market sentiment is crowded around the AI narrative, yet filings document ongoing geopolitical impacts and a guided step-down in China revenue to ~20% in 2026, adding volatility. Given the thin margin of safety at this valuation, the investment call remains 'WAIT,' requiring confirmation from Q1-Q2 2026 results that risks aren't derailing the €34B-€39B sales guidance.

Implication

The elevated valuation leaves minimal room for error, meaning any guide cut or shipment delay from export controls could precipitate sharp downside. While EUV-driven growth supports fundamentals, it's already priced in, demanding flawless execution to unlock further upside. Geopolitical headwinds, including China's revenue normalization and raw material restrictions, pose live threats that could impair revenue conversion. Supply chain fragilities, such as dependency on Carl Zeiss SMT, introduce operational risks not fully discounted in the stock. Therefore, focus on monitoring bookings trends and management's adherence to guidance over the next 3-6 months before considering a position, prioritizing capital preservation amid high uncertainty.

Thesis delta

The new article's emphasis on growth potential does not shift the core thesis, which already acknowledges EUV-driven revenue boosts but stresses overvaluation. It overlooks critical risks detailed in filings, such as export control impacts and supplier constraints, which keep the downside severe. Thus, the thesis remains unchanged: wait for execution proof against geopolitical and supply chain headwinds before investing.